个人情况介绍、概览
杨华丽，女，博士，副教授。2014年毕业于沈阳药科大学，获制药工程学士学位，2020年于同校获中药学博士学位，2020年留校任教。主要研究方向为神经及肿瘤诊疗药物的研发、药物合成工艺的研究。先后以第一作者或通讯作者身份在Eur J Med Chem、Bioorg Chem等药物化学领域知名期刊发表SCI科研论文10余篇，其中中科院药物化学1区论文8篇。近年来作为课题负责人主持新药研究国家重点实验室开放课题1项、辽宁省教育厅项目1项，获2023年“优青”托举计划资助、连云港市博士后科研项目资助，参与国家自然科学基金面上项目1项；主持多项企事业横向课题。
人才称号、社会兼职等
1.沈阳市高层次人才；
2.《中国药物化学杂志》青年编委；
3.沈阳药科大学“基于靶点的药物设计与研究”教育部重点实验室管理委员会秘书。
主要研究方向
研究方向一：神经相关疾病诊疗药物的研发
研究方向二：小分子靶向抗肿瘤药物的研发
研究方向三：药物合成新工艺研究
主持、参与的科研项目（含科研获奖等情况）
1.抗AD文冠果壳活性组分及其衍生物的筛选和优化新策略，新药研究国家重点实验室开放课题，基金编号SIMM2205KF-06（负责人）
2.β-淀粉样蛋白近红外荧光探针的设计、合成及阿尔茨海默病诊断应用研究，辽宁省教育厅高校基本科研项目，基金编号LJKMZ20221368（负责人）
3.齐墩果酸及其皂苷衍生物的设计、合成及抗阿尔茨海默病药理活性研究，连云港市博士后科研资助计划项目，基金编号LYG20210018（负责人）
4.基于肿瘤微环境双重响应的“探针-抑制剂”双功能分子的设计、合成及作用机制研究，国家自然科学基金面上项目，基金编号22177079，排名4/10
5.创新药物合作实验室，横向课题，500万元 （主持人）
6.哈尔滨三联药业股份有限公司，横向课题，200万元 （主持人）
近年来发表代表性论文(限第一作者或通讯作者，SCI须写明影响因子)：
1.Yaoyang Liu; Chao Ma; Yingbo Li; Mengzhen Li; Tao Cui; Xueqi Zhao; Zhenli Li; Hongwei Jia; Hanxun Wang; Xiaomeng Xiu; Dexiang Hu; Ruiwen Zhang; Ningwei Wang; Peng Liu*;Yang Huali*;Cheng Maosheng*.Design, synthesis and biological evaluation of carbamate derivatives incorporating multifunctional carrier scaffolds as pseudo-irreversible cholinesterase inhibitors for the treatment of Alzheimer's disease[J]. European Journal of Medicinal Chemistry, 2024, 265.
2.Xiaomeng Xiu, Mengzhen Li, Dexiang Hu, Hongwei Jia, Hanxun Wang, Yaoyang Liu, Xueqi Zhao, Zhenli Li, Yang Liu,Yang Huali*;Cheng Maosheng*. Potential oral VEGFR2 inhibitors: Treatment of wet age-related macular degeneration[J].Bioorganic Chemistry,144 (2024): 107110.
3.Xiaomeng Xiu, Hongwei Jia, Yaoyang Liu, Xueqi Zhao, Yang Liu,Yang Huali*;Cheng Maosheng*Economical and Practical Process Development for a Novel Multitarget Tyrosine Kinase Inhibitor Vorolanib[J].Organic Process Research & Development,28(2024)492-499.
4.ZhangKaicheng#;LiuYang#;JiaHongwei;WangHanxun;DengMinghui;LiuYaoyang;ZhaoXueqi;XiuXiaomeng;LiZhenli;Yang Huali*;Cheng Maosheng*.Design, synthesis, and evaluation ofN-methyl-propargylamine derivates as isoform-selective monoamine oxidases inhibitors for the treatment of nervous system diseases,Bioorganic Chemistry,2023, 134:106441. (IF=5.307).
5.Zhong Ye; Li Zhining; Jiang Xinyue; Tian Xing; Deng Minghui; Cheng Maosheng;Yang Huali*; Liu Yang*.Identification of Novel Artemisinin Hybrids Induce Apoptosis and Ferroptosis in MCF-7 Cells, International Journal of Molecular Sciences, 2022, 23(24): 15768. (IF=6.208).
6.JiaHongwei#;Yang Huali#;XiongZhiling;DengMinghui;WangTong;LiuYang*;ChengMaosheng*.Design, synthesis and antitumor activity evaluation of novel indole acrylamide derivatives as IMPDH inhibitors,Bioorganic Chemistry,2022, 129:106213. (IF=5.307)
7.Zhang Zuopeng#;Yang Huali#*; Zhong Ye; Wang Yueqing; Wang Jian; Cheng Maosheng; Liu Yang*.Synthesis, Molecular Docking Analysis, and Biological Evaluations of Saccharide-Modified Sulfonam ides as Carbonic Anhydrase IX Inhibitors, International Journal of Molecular Sciences, 2021, 22(24): 13610. (IF=6.208).
8.Yang Huali#; Wang Xiaobing#; Wang Cheng; Yin Fucheng; Qu Lailiang; Shi Cunjian; Zhao Jinhua; Li Shang; Ji Limei; Peng Wan; Luo Heng; Cheng Maosheng*; Kong Lingyi*.Optimization of WZ4003 as NUAK inhibitors against human colorectal cancer, European Journal of Medicinal Chemistry, 2021, 210: 113080. (IF=7.088).
9.Yang Huali; Fang Siqiang; Tang Yanwei; Wang Cheng; Luo Heng; Qu Lailiang; Zhao Jinhua; Shi Cunjian; Yin Fucheng; Wang Xiaobing*; Kong Lingyi*.A hemicyanine derivative for near-infrared imaging of β-amyloid plaques in Alzheimer's disease, European Journal of Medicinal Chemistry, 2019, 179: 736-743. (IF=5.572).
10.Yang Huali; Cai Pei; Liu Qiaohong; Yang Xuelian; Fang Siqiang; Tang Yanwei; Wang Cheng; Wang Xiaobing*; Kong Lingyi*.Design, synthesis, and evaluation of salicyladimine derivatives as multitarget-directed ligands against Alzheimer’s disease, Bioorganic & Medicinal Chemistry, 2017, 25(21): 5917-5928. (IF=2.881)
11.Yang Huali; Cai Pei; Liu Qiaohong; Yang Xuelian; Li Fan; Wang Jin; Wu Jiajia; Wang Xiaobing; Kong Lingyi.Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease, European Journal of Medicinal Chemistry, 2017, 138: 715-728. (IF=4.816)